Response of Plasmodium falciparum to dihydrofolate reductase inhibitors in Malindi, Kenya.
The response of Plasmodium falciparum isolates to dihydrofolate reductase inhibitors (DHFRI) was examined in Malindi, Kenya. All 20 infected children treated with pyrimethamine/sulphadoxine responded. In contrast, after treatment with pyrimethamine, parasitaemia in 9 of 14 infections failed to clear or recrudesced during the seven-day follow-up. In a 48-hour in vitro test, five of six isolates resistant to pyrimethamine in vivo had a minimal inhibitory concentration (MIC) to pyrimethamine greater than or equal to 300 nmoles/1 compared with less than or equal to 100 nmoles/1 for the four sensitive isolates; four isolates did not grow. MIC to M-B 35769, an experimental DHFRI structurally similar to pyrimethamine were the same (six isolates) or 10-fold lower (three isolates). In the laboratory four of five isolates adapted to in vitro culture had the same MICs as in the field while one isolate became less responsive to both drugs. Cycloguanil (the active metabolite of proguanil) was more active in vitro in the laboratory than pyrimethamine or M-B 35769.
D002648:Child; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005493:Folic Acid Antagonists; D006801:Humans; D007630:Kenya; D008288:Malaria / Q000188:drug therapy*; D010963:Plasmodium falciparum / Q000187:drug effects; D002727:Proguanil; D011739:Pyrimethamine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000627:therapeutic use*; D013424:Sulfanilamides / Q000627:therapeutic use*; D014227:Triazines / Q000627:therapeutic use*
D005493:Folic Acid Antagonists; C043001:M&B 35769; D013424:Sulfanilamides; D014227:Triazines; C026009:cycloguanil; D013413:Sulfadoxine; D002727:Proguanil; D011739:Pyrimethamine